Tarsons Products

Tarsons Products reported a consolidated revenue of INR 108 crores for Q3 FY26, marking a 12.8% year-on-year growth. Consolidated EBITDA stood at INR 31.5 crores, with an EBITDA margin of 29.2%. Adjusted cash PAT showed robust growth of 38.6% year-on-year, reaching INR 31.4 crores. However, adjusted PAT grew at a slower pace of 21.4% to INR 6.4 crores, primarily due to higher depreciation expenses of INR 60.6 crores compared to INR 36.35 crores in the previous nine-month period, stemming from the partial capitalization of the Panchla facility.

The Indian plastic labware industry is projected for a healthy CAGR over the next 5-7 years, driven by growth in healthcare, diagnostics, biotechnology, and pharmaceutical research. The Union Government's budget reinforces this outlook with a 10% increase in overall budgetary allocation for healthcare and pharmaceuticals. A significant INR 100 billion allocation over five years for biopharma is expected to boost India's biologics and biosimilars ecosystem, thereby driving incremental demand for high-quality laboratory consumables.

The company is commercializing its INR 600 crores capex from FY21-22 in FY26. This investment was strategically allocated, with 70% dedicated to building newer products like bioprocess containers and cell culture, along with land and building, and only 25-30% for expanding existing capacity. The bioprocess products have been commissioned and are already selling. Management expects new product capacities to reach 15-20% utilization in the first year and 30-35% by the second year, aiming for optimal levels within 2-3 years.

The domestic market is experiencing increased competition and aggressive pricing strategies, a trend that intensified post-COVID. Management noted that many competitors, having expanded capacities during the artificial demand surge, are now facing large fixed cost burdens and are resorting to aggressive pricing to utilize their capacities. Tarsons, however, emphasizes its volume-led growth, established brand, consistent supply, and high-quality products to outperform, leveraging its scale advantage and reliable supply capabilities.

While international trade has faced uncertainties due to geopolitical tensions, recent trade agreements with the EU and US are expected to provide relief. The India-EU FTA will reduce import taxes from 6% to 0%, offering a small but positive impact. More significantly, the India-US FTA, if executed, could reduce taxes from 50% to 18%, which is anticipated to be a major benefit and could significantly expand Tarsons' business in the American market. The company aims to leverage its manufacturing cost advantages and process efficiency to gain momentum in overseas markets.

Nerbe, Tarsons' overseas subsidiary, saw a 22% increase in sales this quarter, primarily driven by rupee depreciation. Management acknowledged the challenging European economic environment but expects future growth for Nerbe to be propelled by the introduction of new products from Tarsons' facilities, particularly in cell culture, and through geographical expansion within the EU. The strategy involves replicating Nerbe's successful model in Germany across other key European geographies.

The company highlighted that the Government e-Marketplace (GeM) system in India has created significant challenges for government business over the last 3-4 years. The L1 (lowest bidder) procurement process often leads to vendors supplying products that do not fully meet customer needs, and customers are compelled to buy them. This lack of transparency and customization has hindered the growth of the standard laboratory consumable business for top players in the government sector.